Salomon Anne - avis, photos, numéro de téléphone et adresse - Hôpitaux vétérinaires à Grand Est - Nicelocal.fr
![HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01158-3/MediaObjects/13045_2021_1158_Fig1_HTML.png)
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
![Bérengère OUINE | Institut Curie, Paris | Département de Recherche Translationnelle | Research profile Bérengère OUINE | Institut Curie, Paris | Département de Recherche Translationnelle | Research profile](https://i1.rgstatic.net/ii/profile.image/439327147728897-1481755162733_Q512/Berengere-Ouine.jpg)
Bérengère OUINE | Institut Curie, Paris | Département de Recherche Translationnelle | Research profile
8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis | PLOS ONE
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8662740/bin/nihms-1731291-f0005.jpg)